Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study uses a computerized method of musical instrument digital interface (MIDI) quantification of performance before and after treatment with botulinum toxin type B (Myobloc ®, Solstice Neurosciences). Myobloc is a purified and diluted form of botulinum toxin used medically to relax unwanted muscle spasms and movements. The aim of the study is to determine the feasibility of quantifying change in performance following treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Columbia University
• Collaborator: Solstice Neurosciences
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA; rimabotulinumtoxinB

Criteria

Inclusion Criteria:

• Focal, task-specific dystonia clinically determined to be the result of a high level of musical skill and intensive performance history

Exclusion Criteria:

• Neurological disorders other than dystonia

• Patients who are clinically depressed, demented or otherwise unable to perform appropriately or sit through 1 hour of testing

• Patients who have undergone pallidotomy, thalamotomy or deep brain stimulator implantations

• Patients who have who recently have taken medications with extrapyramidal or tremorogenic side effects